Genome-based diagnostics and therapeutics in personalized cancer therapy: Can the challenges be overcome?

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

With isolated success - trastuzumab, imatinib, vemurafenib-, the current generation of targeted drugs provides limited benefit for cancer patients. Evidence from phase 3 randomized trials suggests mostly progression-free survival benefit without a true overall survival prolongation. The advent of high-throughput technologies and advances in systems computational biology shape now high expectations for the next-generation cancer-targeted drugs and biomarkers. This new era of personalized medicine raises hope for individual tumor-heterogeneity-based implementation of targeted drugs. Which are the challenges and how could be possible to overcome therapeutic resistance of cancer cells and to increase cancer therapy efficacy and improve oncological outcomes?

Original languageEnglish (US)
Pages (from-to)53-57
Number of pages5
JournalGastric and Breast Cancer
Volume11
Issue number2
DOIs
StatePublished - Apr 2012

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Genome-based diagnostics and therapeutics in personalized cancer therapy: Can the challenges be overcome?'. Together they form a unique fingerprint.

Cite this